---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013872"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:15:36.542139+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Telomir regains Nasdaq compliance on annual meeting requirement

## Summary
- Received letter from Nasdaq on March 30, 2026 confirming compliance with Rule 5620(a).
- Compliance achieved after holding the 2025 Annual Meeting of Shareholders.
- Nasdaq has determined the matter closed.
- No further actions required from the company regarding this deficiency.

## SEC filing metadata
- accession: 0001493152-26-013872
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/0001493152-26-013872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013872
- JSON: https://secwatch.observer/filing/0001493152-26-013872.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.